8-K: Akoya Biosciences Reports Record Q4 Revenue and Projects Operating Cash Flow Breakeven by Year-End 2024

Akoya Biosciences announced record fourth-quarter revenue of $26.5 million and provided a full-year 2024 revenue guidance of $114.0-118.0 million, with a target of operating cash flow breakeven by the end of 2024.

Summary

• Akoya Biosciences reported a 25% increase in revenue for the fourth quarter of 2023, reaching $26.5 million, compared to $21.2 million in the same period of the previous year.
• The company's gross margin improved to 62.7% in Q4 2023, up from 56.8% in Q4 2022, driven by product mix and improved product margins.
• Operating expenses decreased by 11.8% to $26.1 million in Q4 2023, compared to $29.6 million in Q4 2022, due to operating leverage and efficiencies.
• The operating loss for Q4 2023 was $9.4 million, a significant decrease from the $17.6 million loss in the same quarter of the previous year.
• For the full year 2023, Akoya's revenue reached $96.6 million, a 29% increase compared to $74.9 million in 2022.
• The company's gross margin for the full year 2023 was 58.3%, slightly up from 58.0% in 2022.
• Operating expenses for the full year 2023 increased by 4.1% to $114.0 million, compared to $109.5 million in 2022.
• The operating loss for the full year 2023 was $57.7 million, a decrease from the $66.1 million loss in 2022.
• Akoya's installed base of instruments grew by 26.7% to 1,183 by the end of 2023, up from 934 in 2022.
• The number of publications citing Akoya's technology increased by 50.3% to 1,160 by the end of 2023.
• The company is guiding for a full-year 2024 revenue range of $114.0-118.0 million and expects to achieve operating cash flow breakeven by the end of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved margins, reduced operating losses, and a positive outlook for 2024, including a target for operating cash flow breakeven. The company's strategic partnerships and growing installed base further contribute to the positive sentiment.

Positives

• Akoya experienced a significant increase in revenue for both the fourth quarter and full year 2023.
• The company demonstrated improved gross margins in Q4 2023.
• Operating expenses decreased in Q4 2023, indicating improved efficiency.
• The operating loss decreased significantly in both Q4 and full year 2023.
• Akoya's installed base of instruments and the number of publications citing their technology both saw substantial growth.
• The company is projecting strong revenue growth and operating cash flow breakeven by the end of 2024.

Negatives

• Akoya reported an operating loss for both the fourth quarter and full year 2023, although the losses decreased compared to the previous year.
• Operating expenses increased for the full year 2023, although they decreased in Q4.

Risks

• The company's forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially.
• The company's ability to achieve its revenue guidance and operating cash flow breakeven target depends on various factors, including market conditions and execution of its strategic plan.

Future Outlook

Akoya anticipates strong topline growth in 2024 with a revenue guidance range of $114.0-118.0 million and projects operating cash flow breakeven by year end.

Management Comments

• Akoya's successful 2023 performance reflects the high demand for our leading spatial biology solutions and effective execution of our financial and strategic plan, said Brian McKelligon, CEO of Akoya Biosciences.
• We expanded our installed base to nearly 1,200 instruments, improved platform speeds, and simplified workflows with new offerings of reagents and analysis tools.
• We anticipate strong topline growth in 2024 and operating cash flow breakeven by year end.

Industry Context

The announcement highlights the growing demand for spatial biology solutions, a field that is gaining traction in research and clinical applications. Akoya's partnership with Thermo Fisher Scientific and the formation of a Scientific Advisory Board with experts in immunobiology further solidify its position in this competitive market.

Comparison to Industry Standards

• Akoya's 29% revenue growth for the full year 2023 is strong compared to other companies in the life sciences tools and diagnostics sector, which have seen growth rates ranging from single digits to the low 20s.
• The company's focus on spatial biology is a key differentiator, as many competitors are still focused on traditional single-cell analysis.
• Competitors such as NanoString Technologies and 10x Genomics also operate in the spatial biology space, but Akoya's unique platform and partnerships position it well for continued growth.
• The target of operating cash flow breakeven by the end of 2024 is an important milestone, as many companies in this sector are still operating at a loss.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved financial performance positively.
• Employees may be encouraged by the company's growth and positive outlook.
• Customers will benefit from the company's continued innovation and expansion of its product offerings.
• Suppliers may see increased demand for their products and services as Akoya grows.
• Creditors may view the company's improved financial performance as a positive sign.

Next Steps

• Akoya will continue to focus on expanding its installed base of instruments.
• The company will continue to develop and launch new reagents and analysis tools.
• Akoya will work towards achieving its 2024 revenue guidance and operating cash flow breakeven target.
• The company will continue to leverage its partnership with Thermo Fisher Scientific to expand its market reach.

Key Dates

Keywords

Spatial Biology, Akoya Biosciences, Revenue, Gross Margin, Operating Loss, Financial Results, PhenoCycler, PhenoImager, Operating Cash Flow, Installed Base, Publications